ABCL News and Press, AbCellera Biologics Inc. From 02/17/21

Viking Global (Andreas Halvorsen) added new positions in General Electric (GE), AbCellera Biologics (ABCL), The Walt Disney (DIS) and UnitedHealth (UNH), latest 13F filing indicates.Notable increases: Boston Scientific (BSX), Visa (V), Microsoft (MSFT), and Otis Worldwide (OTIS).The...

AbCellera Biologics (ABCL) appointed Ester Falconer, Ph.D. as chief technology officer, effective Jan.28.As CTO, Dr. Falconer will lead AbCellera's long-term strategy in the development, aggregation, and integration of technologies that improve the speed and success of therapeutic a...

AbCellera (Nasdaq: ABCL) announced today that Ester Falconer, Ph.D., has been appointed as Chief Technology Officer (CTO), effective January 28, 2021. As CTO, Dr. Falconer will lead AbCellera’s long-term strategy in the development, aggregation, and integration of technol...

AbCellera (ABCL) shares up nearly 14% premarket after announcing that bamlanivimab, a human antibody discovered by AbCellera and developed with Eli Lilly (LLY), administered with a second Lilly antibody, etesevimab has received Emergency Use Authorization from the FDA for the t...

Bamlanivimab now authorized in two antibody therapy regimens to treat COVID-19 in patients at high risk for hospitalization FDA authorizes new protocols for infusion of bamlanivimab in as few as 16 minutes AbCellera (Nasdaq: ABCL) today announced that bamlanivima...

AbCellera (Nasdaq: ABCL) will announce its fourth-quarter and full-year 2020 financial results on Monday, March 29, 2021 after the U.S. stock markets close and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. The live webcast of t...

In addition to vaccines, it is now the turn of antibodies treatment to play a role in fighting COVID. There are also the diagnostics developers that still have an important stake in enabling recovery in intercontinental travel through rapid testing. Political challenges remain but...

Bamlanivimab’s powerful neutralization of the virus responsible for COVID-19 provides therapeutic backbone for new therapies to expand protection against viral variants AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555), a human antibody discov...

AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555) 2800 mg, a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), and etesevimab 2800 mg (LY-CoV16) together significantly reduced COVID-19 related hospitalizations and deaths (colle...

F-star's antibody engineering platform is seemingly undervalued with comparable companies worth billions of dollars in equity value. The company has an exciting pipeline of early immuno-therapy clinical assets from F-star's recent pivot, 2 years ago, to internal drug development. ...